Laurus Labs
646.25
-18.10(-2.72%)
Market Cap₹34,849.19 Cr
PE Ratio111.87
IndustryHealthcare
Company Performance:
1D-2.72%
1M+6.40%
6M+12.87%
1Y+50.17%
5Y+504.54%
View Company Insightsright
Latest news about Laurus Labs
Laurus Labs Doubles Exports in May, Showcasing Remarkable Growth 3 days ago
Laurus Labs, a pharmaceutical company, has experienced a significant increase in its export performance for May. The company's exports have more than doubled, showing a 104.00% increase compared to the same period last year. This surge indicates an expansion of Laurus Labs' global footprint and suggests potential for enhanced revenue from international sales. The growth also implies improved operational efficiency and a strengthened position in the global pharmaceutical market.
Laurus Labs Reports Strong Q4 FY25, Eyes 24% EBITDA Margin in FY26 Apr 26, 2025
Laurus Labs Secures USFDA Approval for API Facility in Andhra Pradesh Apr 15, 2025
Laurus Labs Reports Robust Export Growth; Q4 FY25 Results Anticipated Apr 11, 2025
More news about Laurus Labs
07Mar 25
Laurus Labs Invests ₹83.3 Crore in KRKA Pharma JV for New Manufacturing Facility
Laurus Labs Limited has approved an investment of ₹83.3 crore in its joint venture, KRKA Pharma Private Limited. The total investment of ₹170 crore, including ₹86.7 crore from co-venturer KRKA d.d., Novo Mesto, Slovenia, will be used to acquire land for a new manufacturing facility, cover initial setup costs, and produce finished products for new markets, including India. The shareholding ratio will remain at 51:49 (KRKA d.d., Novo Mesto : Laurus Labs). The investment, expected to be completed by March 31, 2025, aligns with Laurus Labs' long-term growth strategy in the pharmaceutical industry.
21Feb 25
Laurus Labs Faces Delay in USAID HIV Funds Release Despite Favorable Court Ruling
Laurus Labs, a major pharmaceutical company, has won a court ruling regarding USAID HIV funds but is unable to access them. This delay could impact the company's HIV drug production and distribution, potentially affecting operational targets and financial performance. The situation introduces uncertainty into Laurus Labs' financial outlook, with potential implications for its market position and investor confidence. No official statement has been released by the company regarding this matter.
Laurus Labs
646.25
-18.10
(-2.72%)
1 Year Returns:+50.17%
Industry Peers
Sun Pharmaceutical
1,647.60
(-0.02%)
Divis Laboratories
6,493.00
(-0.86%)
Cipla
1,484.00
(-0.94%)
Dr Reddys Laboratories
1,326.10
(+0.97%)
Torrent Pharmaceuticals
3,164.00
(-1.95%)
Mankind Pharma
2,325.20
(-1.40%)
Zydus Life Science
950.05
(-0.86%)
Lupin
1,931.80
(-1.14%)
Abbott
31,030.00
(-1.69%)
Aurobindo Pharma
1,082.50
(-2.06%)